Intellipharmaceutics Receives Extension of NASDAQ Compliance Deadline

TORONTO, Dec. 29, 2010 (GLOBE NEWSWIRE) — Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel or generic controlled release and targeted release oral solid dosage drugs, today announced that the staff of the Nasdaq Stock Market (the “Staff”) has granted the Company an extension of the [...] http://bit.ly/eULH4N